Regeneron Pharmaceuticals, Inc. REGN announced encouraging initial results from two cohorts of the early-stage study on ...

Regeneron Pharmaceuticals ... with other cancer treatments in patients with relapsed/refractory (R/R) multiple myeloma (MM). Results presented that linvoseltamab in combination with ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our ... with relapsed/refractory (“R/R”) multiple myeloma (“MM”); the likelihood, timing ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab) has been granted conditional marketing approval by the European Commission (EC) to treat relapsed and refractory (R/R) multiple myeloma (MM).

The EC has granted conditional marketing approval to Regeneron Pharmaceuticals’ bispecific antibody Lynozyfic for treating multiple myeloma.

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.

Regeneron’s bispecific antibody linvoseltamab has received conditional approval from the European Commission (EC) for use in relapsed or refractory multiple myeloma. The decision comes just eight ...

Regeneron has since re-filed the BCMAxCD3 drug in the U.S., and it's now awaiting a July 10 decision target date. With linvoseltamab's delayed arrival in the U.S., the multiple myeloma bispecific ...

Michaela Hagenhofer, general manager, commercial operations at Johnson & Johnson Innovative Medicine, explains J&J’s commitment to improving quality of life for those living with multiple myeloma ...